For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

< Back to Agenda
Investment and Reimbursement: How to Bring Europe to the Forefront of the Sector
Friday, September 6, 2024 08:00 AM - 09:00 AM  
F3
Roundtable Session
Moderator:
  • Philip Vanek, PhD, Gamma Biosciences, United States
Panelists:
  • Peter Carlqvist, MSc PhD, Nordic Market Access, Sweden
  • Fredrik Eisner, MBA, Parexel, Sweden
  • Philip Vanek, PhD, Gamma Biosciences, United States
This session will discuss the core bottlenecks in cell and gene therapy development and commercialisation in Europe and the major differences with the US market. The panel will also cover the impact of new legislation and guidelines including the Health Technology Assessment. 

Session Objectives
  1. An understanding of the key differences between the US and European markets for cell and gene therapy developers
  2. Appraisal of the impact of legislation on the development and route to market strategies of European cell and gene therapy companies
  3. An appreciation of the current European investment market and vision for the future

 
Philip Vanek
CTO & Partner
 Gamma Biosciences
 Moderator
Peter Carlqvist
Co-Founder
 Nordic Market Access NMA
 Panelists
Fredrik Eisner MSc
Senior Director
 Parexel
 Panelists
Philip Vanek
CTO & Partner
 Gamma Biosciences
 Panelists
< Back to Agenda